This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Partnering, Business Development & Licensing
search
Drug Development

AdAlta CEO on shark antibody technology

Posted by on 14 July 2017
Share this article

AdAlta is developing a novel technology platform that engineers the key stability features of the antigen binding domain of shark antibodies into human proteins to create unique compounds, known as i-bodies, for therapeutic intervention in disease.
Sam Cobb, managing director and CEO of the Australian biotech, talks to Scrip senior writer Lucie Ellis about the company’s recent public listing and clinical development plans for lead product, AD-114, in idiopathic pulmonary fibrosis.


Interviewer: Lucie Ellis – Senior Writer, Pharma Intelligence In Vivo/Pink Sheet/Scrip
Interviewee: Sam Cobb – Managing Director and CEO, AdAlta

Share this article

Sign up for Partnering, Business Development & Licensing email updates

keyboard_arrow_down